Sodium–Glucose Cotransporter 2 Inhibitor Protection Against Adverse Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes
Clinical Diabetes（2019）
摘要
IN BRIEF New treatments for type 2 diabetes are required to demonstrate cardiovascular safety in dedicated cardiovascular outcomes trials (CVOTs). This article reviews available evidence on cardiovascular, renal, and safety outcomes from CVOTs and real-world analyses of sodium–glucose cotransporter 2 inhibitors, along with considerations for their use in clinical practice.
更多查看译文
关键词
sodium–glucose cotransporter,diabetes,adverse cardiovascular,renal outcomes,inhibitor protection
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要